Ovarian Cancer Market

Market Overview and Size

The global ovarian cancer market is expected to witness significant growth over the forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market. Multiple therapeutic landscapes and family history of ovarian cancer are seen as positive indicators of demand for new ovarian cancer drugs. COVID-19 has also had a major impact on the growth of the market.

Pharmanucleusanalyzes a growth rate of the global ovarian cancer market over the forecast period 2023-2030. The expected CAGR of the global ovarian cancer market tends to be around 24% during the mentioned forecast period. The market was valued at USD 2 Billion in 2021 and it will reach USD 11.18 Billion by 2030. Along with market insights such as market value, growth rate, market segments, geographical coverage, market players and the market scenario, the Market report curated by the Pharmanucleus team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, price analysis, and regulatory framework.

Market Definition

Ovarian cancer is a kind of malignant cancer that arises from the ovaries' and fallopian tubes' epithelium, or outer lining. A BRCA1 or BRCA2 gene mutation, as well as an ovarian cancer family history, are both substantial risk factors for ovarian cancer in women. It is crucial to the healthcare industry and is expected to increase throughout the projected period.

Market Dynamics


  • Increase in Elderly Population

The global hematuria treatment market is expected to experience significant growth due to the projected increase in the geriatric population worldwide. The World Health Organization (WHO) forecasts that the elderly population will reach approximately 2 billion by 2050, compared to 617 million in 2015. With advancing age, individuals become more susceptible to various health conditions, including ovarian cancer infection, which can lead to hematuria (blood in the urine).

The rising incidence of ovarian cancer among the elderly population is a key driver for market expansion. Hematuria, characterized by the presence of blood in the urine, is a common symptom of ovarian cancer and requires prompt diagnosis and treatment. As the geriatric population continues to grow, the demand for effective hematuria treatments will increase, driving market growth.

To cater to the needs of this expanding patient population, healthcare providers and pharmaceutical companies are focusing on developing advanced diagnostic techniques and innovative treatment options for hematuria caused by ovarian cancer. This includes the development of targeted therapies, immunotherapies, and personalized medicine approaches.

Overall, the projected growth of the geriatric population, coupled with the increasing risk of ovarian cancer infection, is expected to propel the global hematuria treatment market during the forecast period. It highlights the need for effective and accessible treatment options to address the growing demand in this patient population.

  • Rising Demand for Oral Drugs

The projected market expansion of oral medications is driven by their widespread availability and practical mode of administration. Capsules and tablets are the most common forms of pharmaceuticals, making them easily accessible to patients. The convenience and ease of use associated with oral medications contribute to their projected growth in the global market. Patients can self-administer oral medications at home, reducing the need for healthcare visits. Additionally, the storage and transportation of oral medications are simple, further enhancing their market appeal. The versatility of oral medications in treating various medical conditions also contributes to their projected role in accelerating the worldwide market expansion.

Market Segmentation

The ovarian cancer market can be further segmented beyond the factors mentioned earlier. Here are additional segmentation criteria:

Treatment Type: Ovarian cancer treatment can include various modalities such as surgery, chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. Segmenting the market based on treatment type helps understand the usage and demand for specific therapies and their effectiveness in different patient populations.

Route of Administration: The route of administration refers to how the treatment is delivered to the patient's body. For ovarian cancer, treatments can be administered orally (pills or capsules), intravenously (injections or infusions), or through other routes like intraperitoneal (directly into the abdominal cavity). Segmenting the market based on the route of administration provides insights into patient preferences, convenience, and treatment adherence.

End-Users: The end-users of ovarian cancer treatments can include hospitals, specialty clinics, oncology centers, and research institutions. Segmenting the market based on end-users helps identify the specific healthcare providers and institutions involved in the diagnosis, treatment, and management of ovarian cancer.

Distribution Channel: The distribution channel refers to the path through which the products or treatments reach the end-users. Ovarian cancer treatments can be distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and specialty distribution centers. Segmenting the market based on distribution channels allows for a better understanding of how treatments are delivered, stocked, and accessed by healthcare providers and patients.


  • Increase in Ovarian Cancer

Ovarian cancer is a significant health concern, ranking as the third most common gynecological cancer globally, following cervical and uterine cancer. The mortality rate associated with ovarian cancer is alarming, with approximately 12,810 women projected to lose their lives to this disease. Furthermore, the American Cancer Society estimates that in 2023, around 19,880 new cases of ovarian cancer will be diagnosed in the United States alone. These statistics highlight the urgent need for effective diagnostics and treatment options, driving the growth of the market. The increasing prevalence of ovarian cancer underscores the importance of research, advancements in medical technology, and the development of innovative therapies to address this critical health issue and improve patient outcomes.

  • Rising Healthcare Awareness

The increasing health awareness among individuals is expected to play a pivotal role in promoting market growth. As people become more informed about their health, they are likely to seek appropriate medications for the treatment of ovarian cancer. Additionally, the introduction of novel drugs specifically designed for ovarian cancer treatment is anticipated to stimulate the market. Researchers are investing in the development of medications that cater to the needs of the market, further enhancing market opportunities. These trends highlight the potential for growth and advancement in the ovarian cancer treatment market, driven by increasing health awareness, the introduction of new drugs, and research initiatives focused on developing market-friendly medications.


  • Lack of Skilled Professionals

Lack of trained professionals who are unfamiliar with the treatment methods of this disease might restrain the growth of the global ovarian cancer market over a forecast period.

  • High Cost

The high cost of treatment options surely limits market growth.

This report discusses recent new developments, trade regulations, import-export analysis, production analysis, value chain optimisation, market share, the impact of domestic and localised market players, and opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growth, niches and application dominance, product approvals, product launches, and For more information on the Global Ovarian Cancer Market, contact Pharmanucleus for an Analyst Brief; our professionals can aid you in making an informed market choice to achieve market growth.

Post COVID Impact

The ovarian cancer market refers to the collective activities related to the diagnosis, treatment, and management of ovarian cancer. Ovarian cancer is a significant global health concern, and the market has witnessed advancements in understanding the disease, improving diagnostic techniques, and developing novel treatment options. However, the market has also experienced the impact of the COVID-19 pandemic.

The COVID-19 pandemic has had a substantial effect on the ovarian cancer market. The diversion of healthcare resources, overwhelmed healthcare systems, and restrictions on non-essential medical procedures have disrupted the diagnosis and treatment of ovarian cancer. Delayed screenings, reduced access to healthcare facilities, and the fear of contracting the virus have led to missed or postponed diagnoses, impacting patient outcomes.

Furthermore, clinical trials for new therapies and drugs have been impacted by the pandemic, leading to delays in research and development efforts. The pandemic has also caused disruptions in the global supply chain, affecting the availability and distribution of ovarian cancer treatments and medications.

However, despite these challenges, the pandemic has also accelerated the adoption of telemedicine and digital health solutions, allowing for remote consultations, monitoring, and support for ovarian cancer patients. Virtual platforms have been utilized to provide patient education, counseling, and emotional support during these difficult times.

Additionally, the pandemic has highlighted the importance of preventive healthcare and early detection. Efforts are being made to raise awareness about the symptoms of ovarian cancer and the need for timely screening. Moreover, collaborations between healthcare providers, researchers, and pharmaceutical companies have become crucial to navigate the post-COVID era and ensure the continued development of innovative treatments and personalized medicine approaches for ovarian cancer.

Market Scope

The global ovarian cancer market is classified into four segments: therapeutic type, administration route, distribution channel, and end user. Growth in these industries will help you analyse weak growth areas in industries and provide users with vital market knowledge and industry insights to help them make strategic decisions to uncover significant market applications.

Treatment Type

  • Chemotherapy
  • Targeted Therapy
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others


  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Regional Analysis

The global ovarian cancer market is analyzed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end user as listed above.

Asia-Pacific is expected to experience the highest growth in the market owing to the presence of key generic pharmaceutical companies in this region and the increase in government initiatives and special communities.

North America dominates the market owing to the increase in the female population as the disease tends to affect females and the wide availability of treatment options.

The country section of the report also provides individual market impacting factors and regulatory changes in the national market that impact current and future market trends. In addition, the presence and availability of global brands and the challenges they face due to significant or rare competition from local and national brands, the impact of domestic tariffs and trade routes are considered while providing a forecast analysis of national data.

Competitive Landscape

The Global Ovarian Cancer Market competitive landscape provides information by competitor. The following information is included: company overview, financials, revenue generated, market potential, R&D investment, new market initiatives, global presence, locations and manufacturing facilities, production capacities, company strengths and weaknesses, product launch, product breadth and breadth, and application dominance. The data shown above are only relevant to the firms' focus on the global Ovarian Cancer market.

Key players operating in the global ovarian cancer market include:

  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd.(Ireland)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Eli Lilly and Company (U.S.)
  • Merck & Co., Inc. (U.S.)
  • Allergan (Ireland)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Cipla Inc. (U.S.)
  • Abbott (U.S.)
  • AbbVie Inc. (U.S.)
  • Merck KGaA (Germany)
  • LEO Pharma A/S (Denmark)
  • Bausch Health Companies Inc. (Canada)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Amneal Pharmaceuticals LLC. (U.S.)

Why Choose Us

Inclusion of Pre-clinical Molecules

Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!


One of our marquee services We profile relevant start-up companies in the market.


Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.

Specialized in Healthcare

Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.